| Patient | Johnny Cash |
|---|---|
| Date of birth | 1932-02-26 |
| Identifiers | MRN HR-ML004-SYN-TD; SSN (made up) 000-04-8125 |
| Document date | 2003-05-29 |
| Author | Gideon Hale, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month diabetes, blood pressure, and eye pressure review. [S]
Mr. Cash returns for his three-month review, nine weeks after sitagliptin and midodrine 2.5 mg were started and five weeks after his annual wellness visit. His fasting home readings now run 120 to 150 mg/dL, with none below 70. He is less lightheaded than before midodrine, but he still feels faint for a minute or two after getting up in the morning and after lunch, and he has had no falls. He takes the last midodrine by mid-afternoon and has no scalp tingling or trouble passing urine. He has started physical therapy for gait and balance, and the low-vision home visit is booked. He uses both eye drops every day without stinging. No eye pressure check was done between visits. He is writing and recording at home. [S]
| Element | Detail |
|---|---|
| Interval change | Less lightheaded; still briefly faint after rising and after lunch; no falls |
| Home glucose | Fasting 120 to 150 mg/dL; none below 70 |
| Midodrine tolerance | Last dose by mid-afternoon; no scalp tingling or urinary retention |
| Rehabilitation | Physical therapy started; low-vision home visit booked |
| Eye drops | Latanoprost and dorzolamide daily; no stinging |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight down 0.7 kg since the wellness visit; no fever |
| Eyes | Positive | Tunnel vision and poor vision in dim light, unchanged; no eye pain or redness |
| Cardiovascular | Positive | Briefly faint after rising and after lunch; no fainting or chest pain |
| Genitourinary | Negative | No difficulty passing urine |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 500 mg oral tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with meals | Oral route | 2001-05-06 to 2003-02-27 | completed | S |
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with meals | Oral route | 2003-02-27 | active | S |
| Sitagliptin 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2003-03-27 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2003-02-27 | active | S |
| Latanoprost 0.005% ophthalmic solution, one drop in each eye at bedtime | One drop in each eye at bedtime | Ophthalmic route | 2000-09-11 | active | S |
| Dorzolamide 2% ophthalmic solution, one drop in each eye twice daily | One drop in each eye twice daily | Ophthalmic route | 2003-02-27 | active | S |
| Midodrine 2.5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PM | One tablet by mouth on waking, at midday, and mid-afternoon; last dose at least four hours before bed | Oral route | 2003-03-27 to 2003-05-29 | completed | S |
| Midodrine 5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PM | One tablet by mouth on waking, at midday, and mid-afternoon; last dose at least four hours before bed | Oral route | 2003-05-29 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2003-05-29 | Body height | 188 | cm | S |
| 2003-05-29 | Body weight | 93.5 | kg | S |
| 2003-05-29 | Body mass index (BMI) [Ratio] | 26.5 | kg/m2 | S |
| 2003-05-29 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2003-05-29 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2003-05-29 | Heart rate | 74 | /min | S |
| 2003-05-29 | Respiratory rate | 16 | /min | S |
| 2003-05-29 | Body temperature | 36.7 | Cel | S |
| 2003-05-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2003-05-29 | Hemoglobin A1c/Hemoglobin.total in Blood | 7.7 | % | <=5.6% | High | S |
| 2003-05-29 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 74 | mg/dL | <=99 mg/dL | Normal | S |
| 2003-05-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 7-56 U/L | Normal | S |
| 2003-05-29 | Right eye Intraocular pressure | 15 | mm[Hg] | 10-21 mmHg | Normal | S |
| 2003-05-29 | Left eye Intraocular pressure | 16 | mm[Hg] | 10-21 mmHg | Normal | S |
| 2003-05-29 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2003-05-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert and well; walks with a cane |
| Eyes | Conjunctivae quiet; eye pressure 15 mmHg right and 16 mmHg left by applanation at the eye clinic today |
| Cardiovascular | Regular rhythm; blood pressure 146/82 mmHg lying, 136/76 mmHg seated, and 114/70 mmHg after three minutes standing, with lightheadedness |
| Feet | Skin intact; no ulcers or calluses; sensory loss to the ankles unchanged; protective shoes |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes mellitus with diabetic autonomic neuropathy; HbA1c above the individualized goal at intake | active | confirmed | E11.43 | S — Synthetic modern diagnosis linked to the publicly reported diabetes and autonomic neuropathy. |
| Neurogenic orthostatic hypotension from diabetic autonomic neuropathy | active | confirmed | I95.1 | S — Synthetic finding; explains the autonomic symptoms once labeled Shy-Drager syndrome. |
| Diabetic distal symmetric polyneuropathy with loss of protective sensation in both feet | active | confirmed | E11.42 | S — Synthetic finding linked to his description of numb lower extremities. |
| Primary open-angle glaucoma, both eyes, severe stage | active | confirmed | H40.1133 | S — Synthetic modern diagnosis; the type and stage are not documented historically. |
| Mild nonproliferative diabetic retinopathy without macular edema, both eyes | active | confirmed | E11.3293 | S — Synthetic finding from the dilated eye examination. |
| Hyperlipidemia | active | confirmed | E78.5 | S — Synthetic finding from the baseline LDL cholesterol. |
| History of recurrent pneumonia | active | confirmed | Z87.01 | S — Synthetic modern coding of the documented recurrent pneumonia; supports pneumococcal vaccination. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HbA1c | Every 3 months until at goal or after a therapy change; every 6 months when stable | Completed today | 7.7%, down from 8.6%; not yet at goal, so repeat in three months |
| Laboratory | Lipid panel after starting a statin | 4 to 12 weeks after a statin starts or changes | Completed today | LDL 74 mg/dL, a 42 percent fall. Drawn at 13 weeks, one week after the window closed, because the panel was scheduled for this review instead of inside the window: a minor deviation from the protocol. No harm resulted; there was no dose decision that an earlier result would have changed |
| Laboratory | ALT | Once before a statin; afterward only for symptoms | Completed today | 27 U/L, normal; no further routine checks |
| Laboratory | ALT, AST, and platelets for FIB-4 | At diagnosis and yearly | Deferred | FIB-4 could not be calculated at intake because no platelet count was drawn with the hemoglobin, a deviation from the protocol. ALT and AST were normal at intake and ALT is normal today, so missed liver scarring is unlikely; AST and a platelet count are added to the annual tests |
| Laboratory | Lipoprotein(a) | Once in adulthood | Deferred | Not yet measured, a deviation from the protocol. It would not change treatment now, since he already takes a high-intensity statin; added to the annual lipid panel |
| Examination | Blood pressure, weight, and BMI | Every visit | Completed today | Seated 136/76 mmHg; weight 93.5 kg |
| Examination | Lying, seated, and standing blood pressure | Every visit | Completed today | Lying 146/82, standing 114/70 mmHg; no supine hypertension |
| Examination | Foot examination (inspection, pulses, monofilament) | Every visit with loss of protective sensation | Completed today | No ulcer; sensory loss unchanged |
| Examination | Tonometry (eye pressure) | Every glaucoma visit; 4 to 6 weeks after adding a drop | Completed today | 15 mmHg right and 16 mmHg left, at target. This is the first check since dorzolamide was added three months ago; the check at four to six weeks was missed (see the four-week note). The pressure has reached target, and the six-month OCT and fields will show whether the delay cost any nerve tissue |
| Examination | Drop adherence, ocular surface, and systemic effects of glaucoma drops | Every visit | Completed today | Both drops used daily; no stinging; no effect on pulse or blood pressure |
| Imaging | OCT of the optic nerve and nerve fiber layer, and visual fields | Every 6 months in severe glaucoma | Due | At the six-month review with the eye clinic |
| Survey | Hypoglycemia review and home glucose log | Every visit | Completed today | No readings below 70 mg/dL |
| Survey | Depression screen (PHQ-2) | At least yearly | Completed today | Score 0 |
| Survey | Tobacco use | Every visit | Completed today | No tobacco use |
| Medication safety | Midodrine safety: lying pressure, timing, and urinary retention | Every visit on midodrine | Completed today | Lying 146/82 mmHg; last dose by mid-afternoon; no retention |
| Medication safety | Vaccination review | Yearly, and as doses fall due | Completed today | Recombinant zoster dose 1 given today; RSV, COVID-19, and tetanus remain due from the wellness visit |
| Referral | Physical therapy and low-vision rehabilitation | After a fall-risk finding | Completed today | Physical therapy under way; low-vision home visit booked |
| Self-management | Diet, orthostatic measures, and foot self-care | Every visit | Completed today | Smaller lunches added; other measures continue |
Goal progress:
Immunizations given today: Recombinant zoster vaccine, dose 1 [S]
Guideline basis: Standards of Care in Diabetes—2025 (2025); Primary Open-Angle Glaucoma Preferred Practice Pattern (2025); CMID: Clinical Monitoring Intelligence Database, diabetes, glaucoma, and hyperlipidemia monographs (2026)
Follow-up: Six-month diabetes review with HbA1c, a basic metabolic panel, urine albumin-creatinine ratio, eye pressure, OCT, and visual fields. Next scheduled visit 2003-08-14: six-month diabetes review with glaucoma imaging. [S]